Hvis LVEF ikke er forbedret eller falder yderligere, bør det kraftigt overvejes at afbryde behandlingen med mindre, at fordelene for den enkelte patient opvejer ulemperne.
If LVEF has not improved, or declined further, discontinuation of Herceptin should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks.